Apparent active transport of MDMA is not mediated by P-glycoprotein: A comparison with MDCK and Caco-2 monolayers

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 5, 2006, Pages 219-227

  Bertelsen, Kirk M ^a   Greenblatt, David J ^a,b   von Moltke, Lisa L ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Active transport; Caco w monolayers; MDCK; MDMA; P glycoprotein

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; CARRIER PROTEIN; GLYCOPROTEIN P; INDOMETACIN; METHAMPHETAMINE; PROBENECID; PROGESTERONE; RHODAMINE 123; RITONAVIR; VERAPAMIL; VERLUKAST;

ACTIVE TRANSPORT; ANIMAL CELL; ARTICLE; CELL LINE; CELL STRAIN; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG EXPOSURE; DRUG TRANSPORT; EPITHELIUM CELL; HUMAN; HUMAN CELL; KIDNEY EPITHELIUM; MONOLAYER CULTURE; NONHUMAN; PROTEIN FUNCTION; STRAIN DIFFERENCE;

ANIMALS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL LINE; DOGS; HUMANS; INDOMETHACIN; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; P-GLYCOPROTEIN; PROBENECID; PROGESTERONE; PROPIONATES; QUINOLINES; RHODAMINE 123; RITONAVIR; VERAPAMIL;

EID: 33746427894     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.501     Document Type: Article

References (41)

1. Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 1986; 18: 305-313.
2. Tehan B, Hardern R, Bodenham A. Hyperthermia associated with 3,4-methylenedioxyethamphetamine ('Eve'). Anaesthesia 1993; 48: 507-510.
3. Cohen RS. Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 1137-1145.
4. Esteban B, O'Shea E, Camarero J, Sanchez V, Green AR, Colado MI. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology (Berl) 2001; 154: 251-260.
5. Ropero-Miller JD, Goldberger BA. Recreational drugs. Current trends in the 90s. Clin Lab Med 1998; 18: 727-746.
6. Kraemer T, Maurer HH. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit 2002; 24: 277-289.
7. Henry JA. Ecstasy and the dance of death. Br Med J 1992; 305: 5-6.
8. De Letter EA, Bouche MP, van Bocxlaer JF, Lambert WE, Piette MH. Interpretation of a 3,4-methylenedioxymethamphetamine (MDMA) blood level: discussion by means of a distribution study in two fatalities. Forensic Sci Int 2004; 141: 85-90.
9. de la Torre R, Farre M, Ortuno J et al. Non-linear pharmacokinetics of MDMA ('ecstasy) in humans. Br J Clin Pharmacol 2000; 49: 104-109.
10. von Moltke LL, Greenblatt DJ. Drug transporters in psychopharmacology - are they important? J Clin Psychopharmacol 2000; 20: 291-294.
11. von Moltke LL, Greenblatt DJ. Drug transporters revisited. J Clin Psychopharmacol 2001; 21: 1-3.
12. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997; 27: 161-170.
13. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-2524.
14. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995; 29: 607-649.
15. van Tellingen O. The importance of drug-transporting P-glycoproteins in toxicology. Toxicol Lett 2001; 120: 31-41.
16. Schinkel AH, Smit JJ, van Tellingen O et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
17. Cho MJ, Thompson DP, Cramer CT, Vidmar TJ, Scieszka JF. The Madin Darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharm Res 1989; 6: 71-77.
18. Horio M, Chin KV, Currier SJ et al. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J Biol Chem 1989; 264: 14880-14884.
19. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 1988; 85: 4486-4490.
20. Crone C, Olesen SP. Electrical resistance of brain microvascular endothelium. Brain Res 1982; 241: 49-55.
21. Wang Q, Rager JD, Weinstein K et al. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm 2005; 288: 349-359.
22. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001; 46: 27-43.
23. Mariadason JM, Arango D, Corner GA et al. A gene expression profile that defines colon cell maturation in vitro. Cancer Res 2002; 62: 4791-4804.
24. Augustijns PF, Bradshaw TP, Gan LS, Hendren RW, Thakker DR. Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. Biochem Biophys Res Commun 1993; 197: 360-365.
25. Hunter J, Hirst BH, Simmons NL. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 1993; 10: 743-749.
26. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 1998; 15: 1160-1167.
27. Perloff MD, Störmer E, von Moltke LL, Greenblatt DJ. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 2003; 20: 1177-1183.
28. Clauwaert KM, Van Bocxlaer JF, De Letter EA, Van Calenbergh S, Lambert WE, De Leenheer AP. Determination of the designer drugs 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxyethylamphetamine, and 3,4-methylenedioxyamphetamine with HPLC and fluorescence detection in whole blood, serum, vitreous humor, and urine. Clin Chem 2000; 46: 1968-1977.
29. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999; 55: 929-937.
30. Prime-Chapman HM, Fearn RA, Cooper AE, Moore V, Hirst BH. Differential MRP1-6 isoform expression and function in human intestinal epithelial Caco-2 cells. J Pharmacol Exp Ther 2004; 311: 476-484.
31. Hirohashi T, Suzuki H, Chu XY, Tamai I, Tsuji A, Sugiyama Y. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). J Pharmacol Exp Ther 2000; 292: 265-270.
32. Walgren RA, Karnaky Jr KJ, Lindenmayer GE, Walle T. Efflux of dietary flavonoid quercetin 4′-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther 2000; 294: 830-836.
33. Olson DP, Scadden DT, D'Aquila RT, De Pasquale MP. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). Aids 2002; 16: 1743-1747.
34. Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos 2000; 28: 329-334.
35. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 1998; 352: 1751-1752.
36. Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999; 159: 2221-2224.
37. Reid G, Wielinga P, Zelcer N et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 2003; 100: 9244-9249.
38. Potschka H, Baltes S, Loscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res 2004; 58: 85-91.
39. Jones K, Bray PG, Khoo SH et al. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? Aids 2001; 15: 1353-1358.
40. Barnes KM, Dickstein B, Cutler Jr GB, Fojo T, Bates SE. Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 1996; 35: 4820-4827.
41. Ketabi-Kiyanvash N, Weiss J, Haefeli WE, Mikus G. P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine. Addict Biol 2003; 8: 413-418.